Related Experiment Video

Updated: May 16, 2026

Functionalized Spirocyclic Heterocycle Synthesis and Cytotoxicity Assay
05:17

Functionalized Spirocyclic Heterocycle Synthesis and Cytotoxicity Assay

Published on: February 9, 2021

Triptolide inhibits MDM2 and induces apoptosis in acute lymphoblastic leukemia cells through a p53-independent

Mei Huang1, Hailong Zhang, Tao Liu

  • 1Department of Pediatrics, Aflac Cancer and Blood Disorders Center, Emory University School of Medicine, Atlanta, Georgia 30322, USA.

Molecular Cancer Therapeutics
|December 18, 2012
PubMed

Insights

Triptolide induces apoptosis in acute lymphoblastic leukemia (ALL) cells by inhibiting MDM2 expression. This mechanism, distinct from cellular stress responses, involves XIAP downregulation, offering a novel therapeutic strategy for MDM2-overexpressing cancers.

Area of Science:

  • Oncology
  • Molecular Biology
  • Pharmacology

Background:

  • Triptolide, a natural product from Tripterygium wilfordii, demonstrates broad-spectrum antitumor activity.
  • Its efficacy is linked to inhibiting pro-proliferative and anti-apoptotic factors in cancer cells.

Purpose of the Study:

  • To investigate the mechanism of triptolide-induced apoptosis in acute lymphoblastic leukemia (ALL) cells.
  • To determine the role of MDM2 oncoprotein in triptolide's anti-leukemic effects.

Main Methods:

  • Treatment of ALL cells overexpressing MDM2 with triptolide.
  • Analysis of MDM2 mRNA and protein levels.
  • Assessment of p53, p21, PUMA, and X-linked inhibitor of apoptosis protein (XIAP) expression and functionality.
  • Cell cycle analysis.

Main Results:

  • Triptolide induced apoptosis in a subset of ALL cells overexpressing MDM2.
  • Triptolide suppressed MDM2 at the transcriptional level, reducing its mRNA synthesis.
  • MDM2 inhibition increased p53 protein levels but did not activate p53 functionality (no p21/PUMA induction or G1 arrest).
  • Triptolide-induced MDM2 downregulation led to increased inhibition of XIAP, distinct from p53-dependent pathways.

Conclusions:

  • Triptolide triggers apoptosis in MDM2-overexpressing ALL cells via MDM2 transcriptional suppression.
  • The mechanism involves increased XIAP inhibition, independent of canonical p53 activation pathways.
  • This suggests a potential therapeutic role for triptolide in MDM2-driven leukemias.

More Related Videos

Comet Assay to Quantify DNA Damage in FLT3 Mutant-expressing 32D Cells after Exposure to Type I and Type II FLT3 Inhibitors04:36

Comet Assay to Quantify DNA Damage in FLT3 Mutant-expressing 32D Cells after Exposure to Type I and Type II FLT3 Inhibitors

Published on: October 17, 2025

Related Concept Videos

Abnormal Proliferation02:23

Abnormal Proliferation

Under normal conditions, most adult cells remain in a non-proliferative state unless stimulated by internal or external factors to replace lost cells. Abnormal cell proliferation is a condition in which the cell's growth exceeds and is uncoordinated with normal cells. In such situations, cell division persists in the same excessive manner even after cessation of the stimuli, leading to persistent tumors. The tumor arises from the damaged cells that replicate to pass the damage to the daughter...
The Intrinsic Apoptotic Pathway01:31

The Intrinsic Apoptotic Pathway

Internal cellular stress, such as cellular injury or hypoxia, triggers intrinsic apoptosis. The B-cell lymphoma 2 (Bcl-2) family of proteins are the primary regulators of the intrinsic apoptotic pathway. For example, during DNA damage, checkpoint proteins, such as Ataxia Telangiectasia Mutated (ATM protein) and Checkpoints Factor-2 (Chk2) proteins, are activated. These proteins phosphorylate p53 which further activates pro-apoptotic proteins, such as Bax, Bak, PUMA, and Noxa, and inhibits...
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Drugs that Stabilize Microtubules01:15

Drugs that Stabilize Microtubules

Microtubules are dynamic structures that undergo cycles of catastrophe and rescue. The microtubules play a central role in cell division by forming the spindle apparatus for segregating the chromosomes. This makes them ideal targets for regulating dividing cells in tumors and malignant cancer cells. Microtubule stabilizing drugs help stabilize the microtubule formation and promote its polymerization. Paclitaxel was the first microtubule stabilizing agent used as anticancer drug in chemotherapy...
Combination Therapies and Personalized Medicine02:50

Combination Therapies and Personalized Medicine

Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
Treatment Resistant Cancers02:56

Treatment Resistant Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...